Psilocybin - COMPASS Pathways
Alternative Names: COMP-360; PsilocybineLatest Information Update: 05 Sep 2025
At a glance
- Originator COMPASS Pathways
- Developer COMPASS Pathways; Imperial College of Science, Technology and Medicine; Johns Hopkins University
- Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Ethylamines; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phosphates; Phytotherapies; Small molecules
- Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Depressive disorders
- Phase II Anorexia nervosa; Bipolar depression; Major depressive disorder; Post-traumatic stress disorders; Somatoform disorders
- Clinical Phase Unknown Autism spectrum disorder
Most Recent Events
- 02 Sep 2025 Updated efficacy and adverse events data from a phase II trial in Post-traumatic stress disorders released by Compass Pathways
- 23 Jun 2025 COMPASS Pathways plans to discuss preliminary phase-III COMP005 trial data with US FDA
- 23 Jun 2025 Interim adverse events and efficacy data from the phase-III COMP005 trial in Depressive disorders released by COMPASS Pathways